{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:08Z","timestamp":1786118948365,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/cad.0b013e32830c2380","type":"journal-article","created":{"date-parts":[[2008,8,8]],"date-time":"2008-08-08T11:46:49Z","timestamp":1218196009000},"page":"837-840","source":"Crossref","is-referenced-by-count":4,"title":["Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy"],"prefix":"10.1097","volume":"19","author":[{"given":"Daris","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Codec\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Foa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El-Serag","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-12-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R4-12-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ssu.2980090403","article-title":"Evolution of surgery in the treatment of hepatocellular carcinoma from the 1950s to the 1990s","volume":"9","author":"Tang","year":"1993","journal-title":"Semin Surg Oncol"},{"key":"R5-12-20210203","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure","volume":"111","author":"Bruix","year":"1996","journal-title":"Gastroenterology"},{"key":"R6-12-20210203","first-page":"341","article-title":"Treatments in hepatology","author":"Makuuchi","year":"1995"},{"key":"R7-12-20210203","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"R8-12-20210203","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1111\/j.1440-1746.1997.tb00516.x","article-title":"Non-surgical treatment of hepatocellular carcinoma","volume":"12","author":"Lin","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-12-20210203","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"R10-12-20210203","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R11-12-20210203","first-page":"194","article-title":"The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy","volume":"89","author":"Kotoh","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"R12-12-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00000421-199808000-00014","article-title":"Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients","volume":"21","author":"Pawarode","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"R13-12-20210203","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer (Phila)"},{"key":"R14-12-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"R15-12-20210203","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha 2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma","volume":"97","author":"Yeo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R16-12-20210203","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00000421-199904000-00024","article-title":"Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication","volume":"22","author":"Patt","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"R17-12-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ajcp\/105.1.65","article-title":"Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients","volume":"105","author":"Nzeako","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"R18-12-20210203","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510280322","article-title":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients","volume":"28","year":"1998","journal-title":"Hepatology"},{"key":"R19-12-20210203","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-002-0503-x","article-title":"Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)","volume":"50","author":"Boucher","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R20-12-20210203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1440-1746.1997.tb00487.x","article-title":"Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation","volume":"12","author":"Chou","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-12-20210203","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10236","article-title":"Factor predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy","volume":"94","author":"Leung","year":"2002","journal-title":"Cancer"},{"key":"R22-12-20210203","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0002-9343(85)90330-4","article-title":"Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival","volume":"78","author":"Ihde","year":"1985","journal-title":"Am J Med"},{"key":"R23-12-20210203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejca.2005.09.034","article-title":"Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level","volume":"42","author":"Boige","year":"2006","journal-title":"Eur J Cancer"},{"key":"R24-12-20210203","first-page":"218","article-title":"Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin","volume":"54","author":"Li","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"R25-12-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000058526","article-title":"Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine","volume":"60","author":"Ulrich-Pur","year":"2001","journal-title":"Oncology"},{"key":"R26-12-20210203","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-12-20210203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-004-0829-7","article-title":"Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma","volume":"54","author":"Jang","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R28-12-20210203","first-page":"1676","article-title":"Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma","volume":"5","author":"Leung","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R29-12-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/02841860500341140","article-title":"Hepatocellular carcinoma: pathological complete response to oral capecitabine, megestrol and thalidomide","volume":"45","author":"Quek","year":"2006","journal-title":"Acta Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32830c2380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:11:37Z","timestamp":1786036297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200809000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32830c2380","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}